Pharma

Your Article Summary

See Latest Articles

Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
Cephalon, 09/25/09

Cephalon, Inc. announced the U.S. Food and Drug Administration has granted a priority review for its supplemental New Drug Application for NUVIGIL(R) Tablets, which was filed in June of this year. The FDA decision on approval of NUVIGIL as a treatment for improving wakefulness in patients with excessive sleepiness associated with jet lag disorder due to eastbound travel is expected by December 2009. There currently is no FDA–approved treatment for jet lag disorder.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Multaq Approved in the European Union for Patients with Atrial Fibrillation
Sanofi-aventis, 12/01/09

FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09

FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
BioMarin, 12/01/09

 See all of Drug/Product Approvals